319 related articles for article (PubMed ID: 26860753)
1. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer.
Rad E; Tee AR
Semin Cell Dev Biol; 2016 Apr; 52():39-46. PubMed ID: 26860753
[TBL] [Abstract][Full Text] [Related]
2. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
3. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
Ratner N; Miller SJ
Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
[TBL] [Abstract][Full Text] [Related]
4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
5. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
7. The NF1 somatic mutational landscape in sporadic human cancers.
Philpott C; Tovell H; Frayling IM; Cooper DN; Upadhyaya M
Hum Genomics; 2017 Jun; 11(1):13. PubMed ID: 28637487
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis and associated tumour suppressor genes.
Zwarthoff EC
Pathol Res Pract; 1996 Jul; 192(7):647-57. PubMed ID: 8880865
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
10. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.
Chai G; Liu N; Ma J; Li H; Oblinger JL; Prahalad AK; Gong M; Chang LS; Wallace M; Muir D; Guha A; Phipps RJ; Hock JM; Yu X
Cancer Sci; 2010 Sep; 101(9):1997-2004. PubMed ID: 20550523
[TBL] [Abstract][Full Text] [Related]
12. Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?
Fareez F; Wang BH; Brain I; Lu JQ
Pathology; 2023 Apr; 55(3):302-314. PubMed ID: 36774237
[TBL] [Abstract][Full Text] [Related]
13. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
14. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
15. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway.
Ozawa T; Araki N; Yunoue S; Tokuo H; Feng L; Patrakitkomjorn S; Hara T; Ichikawa Y; Matsumoto K; Fujii K; Saya H
J Biol Chem; 2005 Nov; 280(47):39524-33. PubMed ID: 16169856
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
17. STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.
Somatilaka BN; Madana L; Sadek A; Chen Z; Chandrasekaran S; McKay RM; Le LQ
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38502231
[TBL] [Abstract][Full Text] [Related]
18. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
[TBL] [Abstract][Full Text] [Related]
19. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
20. Developmental abnormalities and cancer predisposition in neurofibromatosis type 1.
Larizza L; Gervasini C; Natacci F; Riva P
Curr Mol Med; 2009 Jun; 9(5):634-53. PubMed ID: 19601812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]